On Apr. 15, 2021, Merck and Ridgeback Biotherapeutics, and Ridgeback Biotherapeutics announced that based on a planned interim analysis of data from MOVe-IN indicate that molnupiravir is unlikely to demonstrate a clinical benefit in hospitalized patients, who generally had a longer duration of symptoms prior to study entry; therefore, the decision has been made not to proceed to Phase 3.